Cel Sci Corporation (CVM)

[Spideyboy]

I would agree with FM. They effectively only have dilution to keep this thing afloat.

L/C, you say they can't continue diluting, because it's the law. As far as I can see from the SEC, the only thing that relates to a limit on offering shares would be around 50 million USD raise in a 12 month period, which gives them plenty more to go. Admittedly it's in excellent legalese, but that's about it as far as an limit being mentioned.
https://www.sec.gov/info/smallbus/qasbsec.htm#rega

Separately I can see a limit on some Reg D private placements rules, but CVM doesn't need to limit themselves to certain Reg Ds?
http://smallbusiness.chron.com/can-company-raise-capital-issuing-preferred-stock-66502.html

If you can point to your reference, that would be appreciated.


You also say that they only need to get to 75Million Market Cap. That's almost 4 times where they are now. That kind of growth hardly happens on speculation alone with FDA lift and positive Arb.

Also Warfare, why would you think that 0.09 would be a bottom? Stocks can easily go to for example 0.009. Of course that would mean being kicked off our current exchange, but that's ours and CVM's problem.

Additionally, the vast majority of investors will see through an R/S as the trick it is to get back up to pps listing compliance. Most of the time this results in pps dropping significantly after the R/S is completed. So unless they plan on bringing the post R/S price to at least 3-4 USD, which could sincerely drop them to 1.5 - 2USD after the market digests the split, and then easily back to less than 1USD following more dilution, then very little point in bothering with the R/S for pps compliance.

If we're talking an R/S of 5 to 1, up to a 20 to 1, with interim data of something good happening, then maybe the market can think this is reasonable or even a positive thing.

But for us to get to 3USD, that would be at least a 33 to 1, and we have no interim data planned to encourage people it's worth it. So at present rates we're prob talking at 40-50 to 1, cause hey, if we're going for it why not. CVM has in the past done two separate 10 - 1 R/S, won't cut it at present levels.

But the SEC has given CVM more than a year before even needing to consider a split, until the SEC might kick CVM off this exchange, so plenty of time to burn through plenty of cash and further dilute.

Even after the FDA hold lift, there's still minimum over a year to go until phase III data is out. That time also requiring significant money.

Only reason to think this company is going to see a positive bump in the short/mid-term is both the FDA hold together with positive ARB decision. And yes it is most likely to be a bump, as once/if we get that, we're back to square one (with some extra cash) not including the additional recent dilutions with regards what the market can see of CVM's worth. Let's remember as we all know, this shoddy management doesn't care at all about shareholders nor as if this company is winning any points on focusing on 'increasing shareholder value'. Even basic communication is rubbish. Money does not equal management trust.

Would we not think any potential investors with the slightest due diligence, even speculative ones will be concerned about how management will continue to mess-up timeline, money, and pps during the time needed to get Multikine to approval? So yes, we'll get some speculators on board with just lift of the hold and Arb decision, but hardly like the flood gates are going to open.

The 'parabolic' that you speak of, as FM said, would thus most likely only happen on approval, (remember CVM = Multikine). Which now some people may even be concerned about due to the protocol change itself. It takes a decent understanding of the statistics to see the positive reason for the increase in the already large patient sample.

Honestly the only reason I'm still long in CVM is that my shares are not worth selling anymore. I believe in the product's base medical theory, and yes if all goes well then approval will let it go 'parabolic', and then based on almost whatever outstanding share base is left at that point, I should still see some kind of a profit. Even if I'd looked at this company for the first time now, I'd wait to see FDA lift and positive Arb, just to have this on the watch list. Then wait over a year till they are nearer approval for consideration (after likely much more new dilution), and then get in.

This said, I'm happy to see people poke holes in the above with fact/experience based logic/arguments. Not with statements in conjunction with 'I really don't have a great argument that I can explain or experience to base that opinion on'.

JMHO